Press Release Eviden Awarded Contract for “Kaufhaus des Bundes - Next Generation” Project by the Procurement Office of the Federal Ministry of the Interior (BeschA) Together with veenion, Eviden is redesigning the 'KdB NG' procurement platform for more than 480 federal authorities and federal-related institutions Berlin, Deutschland, and Paris, France – May 12, 2025 – Eviden, the Atos Group business leading in digital, cloud, big data and security and IT partner veenion GmbH announce the successful signing ...

Underreported D.E.A. Letter and Policy Position Could be a Game Changer for Mushroom Enthusiasts An Emerging Markets Sponsored Commentary ORLANDO, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- At the Emerging Market Report we are comprised of a team of veteran journalists, authors, former stock brokers, financial professionals, and unabashed opportunists who all come together to publish these tidy missives on our client profiles. We are constantly searching for impactful news that could be gamechangers for the Com ...

This New ESA terminal complements Stellar Blu Sidewinder solutions, positioning Gilat to serve both business and defense aviation markets with a comprehensive multi-orbit offeringPETAH TIKVA, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today the successful completion of a series of test flights featuring its ESR-2030Ku electronically steered antenna (ESA). Conducted ...

Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine could accelerate the pathway to functional eradication of measlesMeasles (rubeola) virus appears to offer an attractive target for best-in-class monoclonal antibody discovery and development utilizing Invivyd technologyMore than 20 million Americans are unvaccinated against measles; U.S. is at risk for losing fun ...

Dorel Juvenile reports strong performanceDorel Home taking further steps to return to profitability MONTRÉAL, May 12, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) today announced its financial results for the first quarter ended March 31, 2025.First quarter revenue was US$320.5 million, down 8.7%, from US$351.1 million a year ago. Reported net loss for the quarter was US$25.3 million or US$0.77 per diluted share compared to US$17.6 million or US$0.54 per diluted share a year ago. The r ...

ALMATY, Kazakhstan, May 12, 2025 (GLOBE NEWSWIRE) -- Joint Stock Company Kaspi.kz (“Kaspi.kz”, “we”) (Nasdaq:KSPI) which operates the Kaspi.kz and Kaspi Pay Super Apps in Kazakhstan and owns 65.41% of Hepsiburada in Türkiye, today published its unaudited consolidated IFRS financial results for the quarter ended 31 March 2025 (“1Q 2025”). 1Q 2025 Highlights Our results for the first quarter of the year were broadly as we expected them to be.1Q 2025 Revenue up 21% year-over-year (“YoY”), net income up 16% YoY ...

The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of scheduleTeva launched two new programs to help people around the world access the medicines they need, for a total of nine programs, surpassing its target of eight programs by 2025More than 99% of Teva employees were trained on compliance and ethics, and more than 40% of its significant suppliers were evaluated for sustainability performanceTeva received im ...

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Tr ...

Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028 WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates an ...

Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedemaZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), t ...